Premium
Ketoconazole as Primary Treatment of Prostatic Cancer
Author(s) -
MOFFAT L. E. F.,
KIRK D.,
TOLLEY D. A.,
SMITH M. F.,
BEASTALL G.
Publication year - 1988
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1988.tb06593.x
Subject(s) - ketoconazole , medicine , primary (astronomy) , cancer , oncology , dermatology , antifungal , physics , astronomy
Summary— Ketoconazole 400 mg 8‐hourly was used as primary hormonal treatment in 12 patients with advanced prostatic carcinoma. Four patients were withdrawn because of side effects and 1 died. The 7 patients who tolerated the drug had a reduction in testosterone and adrenal androgens. Six patients were fully evaluable. There was one partial response with complete remission of symptoms. Two patients enjoyed a subjective response and 3 showed no response. Ketoconazole had an effective biochemical action but the side effects seen in this study severely limit its usefulness. Ketoconazole has now been withdrawn as a treatment for prostatic cancer. However, less toxic derivatives might prove a useful addition to the drugs available to treat this condition.